Our findings indicate that the APL double-resistant cell line (NB4-RAA) and the K-562 AML cell line possess the GHRH receptor (GHRH-R) and are thus susceptible to treatment. The gene discussed is GHRHR; the disease is acute promyelocytic leukemia.